ArticleInternational journal of hematology2025
Risk of ankylosing spondylitis in long-term follow-up of hematopoietic stem cell donors: impact of HLA-B27 status and donation type.
Article in International journal of hematology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Hematopoietic stem cell transplantation (HSCT) is a pivotal curative therapy for various hematologic diseases, and donor safety is paramount. A few cases of ankylosing spondylitis (AS) have been reported in healthy unrelated donors, but the incidence has not been previously described. This retrospective cohort study analyzed 1098 bone marrow (BM) and 3890 peripheral blood stem cell (PBSC) donors between January 1998 and December 2018, along with healthy participants from the donor registry using de-identified data from the Taiwan National Health Insurance Research Database. The overall AS incidences among donors and non-donors were both 0.38%. AS incidence did not differ between BM and PBSC donors and their matched counterparts. Individuals with HLA-B27 exhibited higher incidence rate ratios than those without HLA-B27 in both the BM and PBSC cohorts. In those individuals with HLA-B27, BM donors showed a relative risk of 3.85 (p = 0.0017) compared to non-donors, while the risk for PBSC donors was not significantly higher (1.36, p = 0.339). The findings suggest that while AS incidence among HSC donors is comparable to non-donors, HLA-B27 positivity is the main risk factor associated with AS development, particularly among BM donors. This study provides valuable insights into the safety of HSCT donation and long-term follow-up.
Indexed as
Identifiers
40011352What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.